BioNTech Founders to Launch New mRNA Company & FDA Faces Rare Disease Drug Probe

The landscape of pharmaceutical innovation and regulatory oversight is shifting, with a U.S. Senator launching an investigation into the Food and Drug Administration’s (FDA) recent decisions regarding treatments for rare diseases, and the founders of BioNTech, a key player in the development of the Covid-19 vaccine, preparing to embark on a new venture. These developments, reported on March 10, 2026, signal potential changes in both how novel therapies are assessed and approved, and in the future direction of mRNA technology.

BioNTech Founders Chart New Course for mRNA Research

Ugur Sahin and Özlem Türeci, the married couple who co-founded BioNTech, are planning to transition to a new, unnamed company focused on next-generation mRNA medicines by the end of the year. This move, as STAT News reports, doesn’t represent a departure from mRNA technology altogether, but rather a strategic refocusing of efforts. BioNTech will provide certain rights to its mRNA technology to the new company, while also taking a minority stake.

The rationale behind this split, according to BioNTech, is to unlock greater value for shareholders. The new company will concentrate on the early-stage discovery and development of mRNA-based therapies, while BioNTech will prioritize the commercialization of its existing pipeline, particularly its late-stage cancer-focused programs. These include antibody-drug conjugates, immunotherapies, and further mRNA candidates. Importantly, BioNTech will continue to manufacture and sell its widely used Covid-19 vaccine, developed in partnership with Pfizer. This division of labor aims to streamline operations and accelerate the development of both innovative therapies and established products.

The success of the BioNTech/Pfizer Covid-19 vaccine demonstrated the potential of mRNA technology, which delivers genetic instructions to cells to produce proteins that trigger an immune response. While the vaccine was developed with unprecedented speed, the underlying technology has been in development for decades. MRNA vaccines offer several advantages over traditional vaccine approaches, including faster development times and the ability to quickly adapt to new viral variants. However, challenges remain, including ensuring the stability of mRNA molecules and optimizing delivery to target cells. Further research, as the new company intends to pursue, is crucial to overcoming these hurdles and expanding the applications of mRNA technology beyond infectious diseases.

Senator Johnson Investigates FDA Rare Disease Drug Denials

Simultaneously, political pressure is mounting on the FDA as Senator Ron Johnson, a Republican from Wisconsin, has initiated an investigation into the agency’s recent denials of treatments for rare diseases. Bloomberg News details that Johnson is seeking access to the FDA’s complete response letters – the official notifications sent to drugmakers explaining why their applications have been rejected – and plans to request explanations for specific denials. He is also considering calling FDA Commissioner Marty Makary to testify before the Senate’s Permanent Subcommittee on Investigations, which he chairs.

This investigation follows a series of decisions by the FDA to refuse approval for treatments targeting rare diseases, often requesting additional studies before considering approval. These decisions have sparked significant backlash from patient advocacy groups and investors, who argue that the agency is unnecessarily delaying access to potentially life-saving therapies. Rare diseases, defined as those affecting fewer than 200,000 people in the United States, often lack effective treatments, and the development of new therapies is hampered by small patient populations and high research costs. The FDA’s role in balancing the demand for rigorous safety and efficacy data with the urgent needs of patients with rare diseases is a complex and often contentious issue.

The FDA’s decision-making process involves a thorough review of clinical trial data, manufacturing processes, and proposed labeling. The agency’s primary responsibility is to ensure that approved drugs are safe and effective for their intended use. However, critics argue that the FDA’s standards are often too stringent, particularly for rare diseases where the potential benefits may outweigh the risks. The concept of “acceptable risk” is central to this debate, and the FDA must weigh the potential benefits of a new therapy against the potential harms, considering the severity of the disease and the availability of alternative treatments.

Understanding Complete Response Letters

A complete response letter (CRL) is not necessarily a final rejection. It indicates that the FDA has identified deficiencies in the application that must be addressed before approval can be granted. These deficiencies can range from minor issues with labeling to major concerns about the safety or efficacy of the drug. Drugmakers can respond to a CRL by submitting additional data, conducting further studies, or modifying their application. The FDA will then review the revised application and make a final decision. The process can be lengthy and costly, and there is no guarantee that the FDA will ultimately approve the drug.

The FDA’s current challenges extend beyond rare disease approvals. The agency has faced scrutiny in recent years regarding its approval processes, particularly in light of concerns about the opioid crisis and the accelerated approval of certain drugs. These challenges highlight the need for ongoing evaluation and improvement of the FDA’s regulatory framework to ensure that it effectively protects public health while fostering innovation.

What’s Next for FDA Oversight and mRNA Innovation?

Senator Johnson’s investigation is likely to intensify scrutiny of the FDA’s decision-making processes and could lead to calls for legislative reforms. The agency will likely face pressure to provide greater transparency and responsiveness to patient advocacy groups. The outcome of the investigation could influence future FDA policies regarding the approval of drugs for rare diseases and potentially impact the agency’s overall regulatory approach.

Regarding BioNTech, the success of the new mRNA-focused company will depend on its ability to attract funding, recruit top talent, and translate its research findings into viable therapies. The company will face competition from other players in the mRNA space, including Moderna and CureVac. The future of mRNA technology hinges on continued innovation and investment, as well as the ability to overcome the remaining technical challenges. The World Health Organization provides further information on the science behind mRNA vaccines and their potential applications.

Both developments – the Senator’s probe and the BioNTech split – underscore the dynamic interplay between scientific innovation, regulatory oversight, and public health needs. Continued dialogue and collaboration between these stakeholders are essential to ensure that patients have access to safe and effective therapies while fostering a vibrant and innovative pharmaceutical industry. For ongoing updates on FDA actions, the agency’s website (https://www.fda.gov/) is a primary source of information.